Core Viewpoint - The general manager of Huatai Medical, Cheng Zhenghui, has sold 2% of his shares for nearly 700 million yuan at a price significantly lower than the market price, with the buyer being Shenzhen Mindray Technology, a subsidiary of Mindray Medical, a leading player in the A-share medical device sector [1][2][3]. Summary by Relevant Sections Shareholding Changes - Cheng Zhenghui reduced his holdings by 2% (2,820,275 shares) from September 3 to September 11, 2025, at a price of 248.20 yuan per share, totaling approximately 699.99 million yuan [3][4]. - After the sale, Cheng's ownership decreased to 16.70% [5]. Market Price Comparison - During the reduction period, Huatai Medical's stock price remained above 300 yuan, closing at 309.53 yuan on September 11, indicating a 25% premium over the transaction price [5][6]. Buyer Information - The buyer, Shenzhen Mindray Technology, increased its stake in Huatai Medical to 26.54% after acquiring shares from Cheng, reflecting a strategic move to consolidate control [8][9]. Company Performance - Huatai Medical has shown impressive growth, with revenue increasing from 479 million yuan in 2020 to 2.066 billion yuan in 2024, and net profit rising from 111 million yuan to 673 million yuan during the same period [9]. - The company's gross margin improved from 70.36% to 72.31%, and net margin increased from 21.73% to 31.86% [9]. Industry Context - In contrast, Mindray Medical has faced a decline in performance, with a revenue drop of 18.45% to 16.743 billion yuan and a net profit decrease of 32.96% to 5.069 billion yuan in the first half of 2025 [10]. - However, Mindray Medical anticipates a turnaround in the third quarter of 2025, with expected revenue growth driven by international markets [10].